Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

BACKGROUND: Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschetta, Michele, Mak, Gabriel, Hauser, Joana, Davies, Catriona, Uccello, Mario, Arkenau, Hendrik-Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223353/
https://www.ncbi.nlm.nih.gov/pubmed/28078189
http://dx.doi.org/10.1186/s40164-016-0061-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223353/
https://www.ncbi.nlm.nih.gov/pubmed/28078189
http://dx.doi.org/10.1186/s40164-016-0061-2

Ejemplares similares